New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma


  • Study

    Randomized, double-blind, placebo-controlled, multicenter trial (ECHO)
    Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598)
    Acalabrutinib + R-Bendamustine x 6 => rituximab-acalabrutinib maintenance vs. R-Bendamustine + placebo x 6 => rituximab + placebo maintenance



  • Efficacy

    ORR; 91% vs. 88% (BR + acalabrutinib vs. BR + placebo)
    CR: 67% vs. 54%
    mPFS 66.4 mos vs. 49.6 mos (HR: 0.73 [0.57 – 0.94])



  • Safety

    Grade >=3 AEs: Neuropenia (56% vs. 51%), Rash (12% vs. 3%),



  • FDA Package Insert for Acalabrutinib

    FDA FDA Package Insert for Acalabrutinib

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Ulas D. Bayraktar, MD on Jan 19, 2025